UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
NEW YORK, March 17, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Psychemedics Corporation (“Psychemedics”) (NASDAQ:PMD) between February 28, 2014 and January 30, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Daly v. Psychemedics Corporation, et al. (Case No. 1:17-cv-10186) in the USDC for the District of Massachusetts. Click here to view the complaint. To get more information go to:
http://www.zlk.com/pslra/psychemedics-corporation
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, among other allegations, throughout the Class Period Psychemedics issued materially false and/or misleading statements and/or failed to disclose that Psychemedics’ Brazilian distributor, Psychemedics Brazil, was engaged in illegal anti-competitive practices and may be subject to further investigation by Brazil’s Administrative Council for Economic Defense as a result of this conduct.
On January 31, 2017, Psychemedics issued a press release announcing that a Brazilian court had found Psychemedics Brazil in violation of anti-competition laws and is liable for millions in losses.
Take Action: if you suffered a loss in Psychemedics you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
